Hepalink Pharmaceutical Holdings Limited (Hepalink Medicine-B) submitted the next day disclosure report on September 19, 2024, disclosing its shareholding changes. The report shows that as of September 17, 2024, Hepalink Medicine had 768,226,410 issued shares and 650,000 treasury shares. On September 19, 2024, the company repurchased 100,000 ordinary shares at a repurchase price of HKD 1.2486 per share, reducing the issued shares to 768,126,410 shares and increasing the treasury shares to 750,000 shares. The share repurchase was approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. The repurchased shares will be held as treasury shares and will not be cancelled. In addition, the company confirmed that from the date of the share repurchase until October 19, 2024, there will be no new share issuance or further sale or transfer of treasury shares.

Hepalink Pharmaceutical Holdings Limited (Hepalink Medicine-B) submitted the next day disclosure report on September 19, 2024, disclosing its shareholding changes. The report shows that as of September 17, 2024, Hepalink Medicine had 768,226,410 issued shares and 650,000 treasury shares. On September 19, 2024, the company repurchased 100,000 ordinary shares at a repurchase price of HKD 1.2486 per share, reducing the issued shares to 768,126,410 shares and increasing the treasury shares to 750,000 shares. The share repurchase was approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. The repurchased shares will be held as treasury shares and will not be cancelled. In addition, the company confirmed that from the date of the share repurchase until October 19, 2024, there will be no new share issuance or further sale or transfer of treasury shares.